MXCT
MaxCyte, Inc.
MXCT offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over MXCT overall, supported by stronger fundamentals and lower modeled downside.
MXCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
MXCT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MXCT PE Valuation
MXCT has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MXCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect MXCT's revenue to grow, with its earnings and profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MXCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.25 | +$0.19 |
| Q2 2026 | -$0.32 | +$0.11 |
| Q1 2026 | -$0.36 | +$0.04 |
| Q4 2025 | -$0.42 | -$0.03 |
| Q3 2025 | -$0.44 | -$0.10 |
| Q2 2025 | -$0.43 | -$0.09 |
| Q1 2025 | -$0.40 | -$0.05 |
| Q4 2024 | -$0.39 | -$0.02 |
MXCT is still losing money, but less than at its worst: $0.25 per share over the past year, against $0.44 at its worst in late 2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MXCT on earnings quality, reporting a profit while its opponent remains loss making.
MXCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.2M | +49% |
| Q2 2026 | $7.3M | -15% |
| Q1 2026 | $9.7M | -7.1% |
| Q4 2025 | $7.3M | -16% |
| Q3 2025 | $6.8M | -16% |
| Q2 2025 | $8.5M | -18% |
| Q1 2025 | $10.4M | -8.4% |
| Q4 2024 | $8.7M | -45% |
MXCT's revenue is recovering but still below its 2023 peak: $10M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +148 points |
| Q2 2026 | -141% | +27 points |
| Q1 2026 | -64% | +54 points |
| Q4 2025 | -154% | -5.4 points |
| Q3 2025 | -207% | -35 points |
| Q2 2025 | -167% | -53 points |
| Q1 2025 | -118% | -10 points |
| Q4 2024 | -148% | -97 points |
MXCT's operating margin was −60% last quarter, up 148 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MXCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MXCT on profitability, with a higher operating margin.
MXCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.6M | +$2.2M |
| Q2 2026 | -$4.7M | +$5.7M |
| Q1 2026 | -$8.2M | +$6.8M |
| Q4 2025 | -$2.9M | +$5M |
| Q3 2025 | -$7.8M | -$3M |
| Q2 2025 | -$10.4M | -$5.3M |
| Q1 2025 | -$15.1M | -$3.7M |
| Q4 2024 | -$8M | -12010% |
MXCT has burned cash in almost every quarter: −$21M over the past year, against −$41M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MXCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
MXCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.1% | -3.3M shares |
| 1 year | -2.9% | -3.1M shares |
| 3 years | +0.1% | +88.2K shares |
| 5 years | +22% | +18.8M shares |
| Available history | +80% | +46.1M shares |
MXCT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4M |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MXCT Net Leverage
MXCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MXCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.2 | Neutral |
| Stochastic | 49.8 | Neutral |
MXCT's weekly RSI is 49 (neutral) and its Stochastic is 50 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MXCT PE vs Healthcare Sector
MXCT has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MXCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.25 | 4.8% below |
| 20 week MA | $1.23 | 3.3% below |
| 50 week MA | $1.12 | 6.2% above |
| 100 week MA | $1.84 | 35% below |
| 200 week MA | $3.06 | 61% below |
MXCT's trend is mixed: it's above one of its five weekly moving averages, and 61% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MXCT on trend strength, trading above more of its moving averages.
MXCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.0 | $10.8 | -36% |
| 2022 | $10.8 | $5.01 | -54% |
| 2023 | $5.01 | $4.70 | -6.2% |
| 2024 | $4.70 | $4.13 | -12% |
| 2025 | $4.13 | $1.61 | -61% |
| 2026 YTD | $1.61 | $1.19 | -26% |
MXCT has finished every year since 2021 lower, and it's down 26% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MXCT on returns for 2026, with the stronger performance.